|
gptkbp:instanceOf
|
gptkb:drug
statin
cholesterol-lowering agent
|
|
gptkbp:approvedBy
|
1997
|
|
gptkbp:ATCCode
|
gptkb:C10AA06
|
|
gptkbp:brand
|
Baycol
Lipobay
|
|
gptkbp:CASNumber
|
145599-86-6
|
|
gptkbp:category
|
lipid-lowering agent
|
|
gptkbp:contraindication
|
pregnancy
breastfeeding
active liver disease
|
|
gptkbp:developedBy
|
gptkb:Bayer_AG
|
|
gptkbp:drugClass
|
statin
|
|
gptkbp:eliminationHalfLife
|
2-3 hours
|
|
gptkbp:form
|
gptkb:tablet
|
|
gptkbp:hasMolecularFormula
|
C26H34FNO5
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Cerivastatin
|
|
gptkbp:interactsWith
|
gptkb:cyclosporine
gptkb:gemfibrozil
gptkb:fibrates
gptkb:erythromycin
niacin
|
|
gptkbp:KEGGID
|
D00223
|
|
gptkbp:legalStatus
|
withdrawn
|
|
gptkbp:mechanismOfAction
|
HMG-CoA reductase inhibitor
|
|
gptkbp:metabolism
|
gptkb:CYP2C8
gptkb:CYP3A4
|
|
gptkbp:molecularWeight
|
451.55 g/mol
|
|
gptkbp:origin
|
synthetic
|
|
gptkbp:pregnancyCategory
|
gptkb:X_(US)
|
|
gptkbp:PubChem_CID
|
60854
54819
CHEMBL1201352
DB00439
|
|
gptkbp:retired
|
rhabdomyolysis risk
fatal adverse effects
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
muscle pain
liver enzyme abnormalities
rhabdomyolysis
|
|
gptkbp:synonym
|
BAY w6228
cerivastatin sodium
|
|
gptkbp:UNII
|
N9YNS0M02X
|
|
gptkbp:usedFor
|
gptkb:familial_hypercholesterolemia
dyslipidemia
|
|
gptkbp:withdrawn
|
2001
|
|
gptkbp:bfsParent
|
gptkb:C10AA
|
|
gptkbp:bfsLayer
|
7
|